

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Docket Number: INFORMATION DISCLOSURE 11245/46405 STATEMENT Art Unit Application Number Examiner Filing Date 1642 10/661,881 September 11, 2003 To Be Assigned Inventor(s) Invention Title WAKSALet al. TREATMENT OF HUMAN TUMORS WITH RADIATION AND INHIBITORS OF GROWTH

Address to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FACTOR RECEPTOR TYROSINE KINASES

hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Vawrence P. Casson (Reg. No. 46,606)

- In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance 1. with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
- Except as otherwise indicated, copies of the references are not enclosed since they 2. were previously cited by or submitted to the Patent Office in prior patent application Serial No. 09/312,286, filed May 14, 1999, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

Dated: Oc7. 7, 2004

By:

Lawrence P. Casson (Reg. No.46,606)

KENYON & KENYON

One Broadway

New York, New York 10004

(212) 425-7200 (Telephone)

(212) 425-5288 (Facsimile)

CUSTOMER NO. 26646

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO FORM 1449

ATTY. DOCKET NO. 11245/4740	SERIAL NO. 10/661,881		
APPLICANT:, WAKSAL t al.			
FILING DATE September 11, 2003	GROUP 1642		

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	4,943,533	July 1990	Mendelsohn	.		
	5,891,996	Артіl 1999	Mateo de Acosta del Rio	<u> </u>		
	5,558, 864	September 1996	Bending			
	4,510,924		Gray			
	4,763,642		Horowitz	<u> </u>		ļ
	4,846,782		Bonnem	<u> </u>		
	5,656,655		Spada et al.			<u> </u>
	5,646,153		Spada et al.	-	ļ	<u> </u>
	5,679,683		Bridges et al.	<u> </u>		
	5,616,582		Barker	<u> </u>	<u> </u>	
	5,196,446		Levitzki et al.		<u> </u>	ļ
	5,736,534	April 1998	Arnold			
	*5,707,632		Williams et al.			<u> </u>
	*4,816,397					<u> </u>
	*4,816,567					
	*5,225,539				-	ļ
	*5,658,570				ļ	┼
	*5,693,780					

^{*}Copy of reference enclosed

FOREIGN PATENT DOCUMENTS

D20 0.111 (2.1			COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	DOCUMENT NUMBER	T DATE				YES	NO
	WO 96/40210	December 19, 1996	PCT				-
	*EP 502 812			ļ			<u> </u>
	*WO 93/21319						ļ
	*EP 239 400						<u> </u>
	*WO 89/09622						
	*EP 338 745						-
	*EP 331 424						

^{*}Copy of reference enclosed.

OTHER DOCUMENT

XAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Goldkorn et al., "EGF receptor phosphorylation is affected by ionizing radiation", Biochimica et Biophysica Acta 1358, 1997, pp. 289-299
	Saleh et al., "Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and Radiation", Cancer Biotherapy & Radiopharmaceuticals", Vol. 14, No. 6, 1999, pp. 451-463
	Buchsbaum, D. et al., "Invitro and in vivo evaluation of the cytotoxicity of radiation combined with chimeric monoclonal antibody to the opidermal growth factor receptor," Proceeding of the American Association for Cancer Research, Vol. 37, March 1996
	Chi Liu and Ming-Sound Tsao, "In Vitro and in Vivo Expression of Transforming Growth Factor-∝ and Tyrosine Kinase Receptors in Human Non=Small-Cell Lung Carcinomas," American Journal of Pathology, Vol. 142, No. 4, Apr. 1993, pp 1155-1162
	Balaban, et al., Biochim. et Biophysica Acta 1314, 147-156 (1996)
	Snelling, Hybridoma 14, 111-114 (1995)
	Bender et al., Hybridoma 14, 129-134 (1995)
	Brady et al., Journal of Neurosurgical Sciences 34, 243-249 (1990)
	Brady et al., Int. J. Radiation Oncology Biol. Phys. 22, 225-230 (1992)
	Bender et all, Anticancer Research 17, 1797-1802 (1997)
	Saleh et al., Abstract 4197 in Proceedings of the American Association for Cancer Research, 37, 612 (1996)
	Dobelbower, Int. J. Radiation Oncology biol. Phys. 39, 31-37 (1997)
	Lattanzi et al., Int. J. Radiation Oncology Biol. Phys., 38, 569-573 (1997)
	Willem et al., Ophthalmology 104, 1475-1479 (1997)
	Prewett et al., Journal of Imunotherapy 19, 419-427 (1997)
	Baselga et al., Journal of the National Cancer Institute 85, 1327-1333 (1993)
	Ciardiello et al., Clinical Cancer Research 1, 161-167 (1995)
	Ennis, Molecular Endocrinology 3, 1830-1838 (1989)
	Fry et al., Science 62, 1093-1095 (1994)
	Osherov et al., Journal of Biological Chemistry 268, 11134-11142
	Batley et al., Life Sciences 62, 143-150 (1998)
	Panek et al., Journal of Pharmacology and Experimental Therapeutics 1433-1444
	Parrizas et al., Endocrinology 138, 1427-1433 (1997)
	Osband et al., Problems in the Investigational Study and Clinical use of cancer immunotherapy, Immunotherapy, pp. 19
	*Masui et al, Cnacer Res. 44, 5592-5598 (1986)
	*Aboud-Pirak et al., Journal of the National Cancer Institute 80,1605-1611 (1998)
	*Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85, 2444-2448 (1998)
	*Kohler and Milstein in Nature 256, 495-497 (1975)
	*Burdon et al., Eds, Laboratoty techniques in Biochemistry and molecular Biology, Vol. 13, Elsevier Science Publisher Amsterdam (1985
	*Co et al., Nature 351, 501-502 (1992)
	*Queen et al., Proc. Natl. Acad. Sci, 86, 10029-1003 (1989)

^{*}Copy of reference enclosed.

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NY01 735284 v1